Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

WELL Health Technologies Corp T.WELL

Alternate Symbol(s):  WHTCF | T.WELL.DB

WELL Health Technologies Corp. is a Canada-based practitioner-focused digital healthcare company. Its healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. Its business units include Canadian Patient Services, WELL Health USA Patient and Provider Services, and SaaS and Technology Services. Its solutions enable more than 38,000 healthcare providers between the United States and Canada and power owned and operated healthcare ecosystem in Canada with over 200 clinics supporting primary care, specialized care, and diagnostic services. In the United States its solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL Health USA Patient and Provider Services consists of four assets: CRH Medical, Provider Staffing, Circle Medical and Wisp. It provides cybersecurity protection and patient data privacy solutions.


TSX:WELL - Post by User

Post by retiredcfon Apr 05, 2024 9:53am
304 Views
Post# 35972471

TD

TD

Have an $8.00 Target. GLTA

 

HIGHLIGHTS FROM INVESTOR MEETINGS: LOOKING TO BE MORE CANADIAN
 

THE TD COWEN INSIGHT
 

Earlier this week, we hosted investor meetings with CEO Hamed Shahbazi. WELL is our top pick. We believe it has a lucrative long-term growth opportunity ahead, as it further consolidates the very fragmented Canadian clinic market. The potential sale of some/all of its U.S. businesses are key catalysts. We think the post-Q4 sell-off is unwarranted and has created a compelling buying opportunity.
 

Impact: NEUTRAL
 

Strong tailwinds in Canada. We believe WELL is ideally positioned to continue capitalizing on its dominant leadership position in the highly fragmented Canadian clinic market (<1% market share). Numerous factors including chronic doctor shortages and burnout is allowing WELL to "absorb" more clinics for nominal consideration, with ~20 of the ~50 opportunities in its M&A pipeline being clinic absorption candidates. WELL is facing limited competition for these clinics, as we think its scale, clinic transformation expertise, and unrivaled tech- enabled suite of clinic software/services give it a significant competitive advantage.
 

Also, reimbursement rates continue to rise in Canada, in some cases significantly (i.e., well above inflation), as governments look to address the large (family) doctor shortage. The expected ~20% boost to reimbursement rates in Manitoba is making WELL's recent absorption of the Manitoba Clinic even more attractive.
 

U.S. businesses for sale at the right price. We believe inbound interest in Wisp may have spurred the current sale/monetization processes for Wisp and Circle. We think the sale of Circle and/or Wisp could net WELL ~$95mm-$235mm, which would be used to buyback stock and repay debt.

Given the very attractive dynamics in the Canadian market, where WELL is focusing its capital deployment, and management's view that the market is undervaluing its U.S. businesses (which we agree), we believe WELL may sell some or all of its U.S. businesses, including CRH. We believe WELL becoming a Canadian healthcare pure-play would dramatically simplify the story, increase investor interest, and drive a positive re-rating.

 

Margins set to rebound. Mr. Shahbazi reiterated that margins should begin rebounding in Q2/F24, aided by benefits from its enterprise-wide cost optimization initiative that is generating millions of dollars in annual savings, and clinic transformation work at the MCI clinics and Manitoba Clinic.

 

Hidden value...HEALWELL investment is worth >$90mm (>10% of WELL's market cap). We believe investors are overlooking WELL's HEALWELL investment. Netting off its HEALWELL investment would reduce WELL's EV/EBITDA multiple by >0.5x.

 
<< Previous
Bullboard Posts
Next >>